Moleculin Biotech Stock Forecast, Price & News

Wall Street analysts have given Moleculin Biotech a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Moleculin Biotech wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Moleculin Biotech saw a drop in short interest in July. As of July 30th, there was short interest totaling 771,800 shares, a drop of 18.7% from the July 15th total of 949,900 shares. Based on an average daily trading volume, of 266,500 shares, the days-to-cover ratio is currently 2.9 days. Currently, 2.9% of the company's stock are sold short.
View Moleculin Biotech's Short Interest.

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Moleculin Biotech.

Moleculin Biotech, Inc. (NASDAQ:MBRX) released its quarterly earnings results on Tuesday, August, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.04.
View Moleculin Biotech's earnings history.

Moleculin Biotech's stock was trading at $3.0306 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MBRX stock has increased by 2.6% and is now trading at $3.11.
View which stocks have been most impacted by COVID-19.

Moleculin Biotech shares reverse split on Monday, February 1st 2021. The 1-6 reverse split was announced on Friday, January 29th 2021. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 29th 2021. An investor that had 100 shares of Moleculin Biotech stock prior to the reverse split would have 17 shares after the split.

Some companies that are related to Moleculin Biotech include Enochian Biosciences (ENOB), Neoleukin Therapeutics (NLTX), UroGen Pharma (URGN), Verona Pharma (VRNA), Capstar Special Purpose Acquisition (CPSR), Theratechnologies (THTX), Esperion Therapeutics (ESPR), CytomX Therapeutics (CTMX), Fortress Biotech (FBIO), Molecular Templates (MTEM), Verrica Pharmaceuticals (VRCA), Immutep (IMMP), Athersys (ATHX), Cogent Biosciences (COGT) and Angion Biomedica (ANGN).
View all of MBRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX), Dynavax Technologies (DVAX), OPKO Health (OPK), SCYNEXIS (SCYX) and Exelixis (EXEL).

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

Moleculin Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.68%), Geode Capital Management LLC (0.84%), State Street Corp (0.21%), Citadel Advisors LLC (0.13%), XTX Topco Ltd (0.12%) and GSA Capital Partners LLP (0.11%).
View institutional ownership trends for Moleculin Biotech.

MBRX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, State Street Corp, XTX Topco Ltd, GSA Capital Partners LLP, Goldman Sachs Group Inc., Virtu Financial LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Moleculin Biotech or or view top insider-buying stocks.

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MBRX stock can currently be purchased for approximately $3.11.

Moleculin Biotech has a market capitalization of $88.80 million. The company earns $-17,350,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

Moleculin Biotech employs 13 workers across the globe.

The official website for Moleculin Biotech is www.moleculin.com.

Moleculin Biotech is headquartered at 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007.

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at (713) 300-5160 or via email at [email protected]